Literature DB >> 40642

Beta-adrenoceptor agonist activity of labetolol on the isolated uterus of the rat.

B Carey, E T Whalley.   

Abstract

Isoprenaline produced dose-dependent reductions of responses of the isolated uterus of the rat produced by an EC(80) of acetylcholine. Propranolol acted as a competitive antagonist to isoprenaline. Labetolol also reduced the acetylcholine-induced contractions but was much less potent than isoprenaline. The greatest reduction was smaller than that produced by isoprenaline. Propranolol antagonized the lower doses of labetolol. It is suggested that labetolol possesses partial agonist activity at the beta-adrenoceptors of the rat isolated uterus.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 40642      PMCID： PMC2043602     

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  10 in total

Review 1.  The mechanism of the utero-inhibitory effect of beta-sympathomimetics.

Authors:  A J Brugger
Journal:  Pharmacol Ther B       Date:  1975

2.  THE ADRENERGIC RECEPTIVE MECHANISM OF THE RAT UTERUS.

Authors:  B LEVY; S TOZZI
Journal:  J Pharmacol Exp Ther       Date:  1963-11       Impact factor: 4.030

3.  The mechanism of uterine inhibitory action of relaxin-containing ovarian extracts.

Authors:  A D RUDZIK; J W MILLER
Journal:  J Pharmacol Exp Ther       Date:  1962-10       Impact factor: 4.030

Review 4.  Perspectives in adrenergic beta-receptor blockade.

Authors:  J D Fitzgerald
Journal:  Clin Pharmacol Ther       Date:  1969 May-Jun       Impact factor: 6.875

5.  The effects of alpha- and beta-adrenoceptor blocking agents on the responses of the rat uterus to catecholamines throughout the oestrus cycle.

Authors:  K R Butterworth; M J Randall
Journal:  Br J Pharmacol       Date:  1970-09       Impact factor: 8.739

6.  Labetalol in long-term treatment of hypertension.

Authors:  B N Prichard; A J Boakes
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

7.  Differentiation of receptor systems activated by sympathomimetic amines.

Authors:  A M Lands; A Arnold; J P McAuliff; F P Luduena; T G Brown
Journal:  Nature       Date:  1967-05-06       Impact factor: 49.962

8.  Investigation of adrenaline reversal in the rat uterus by the induction of resistance to isoprenaline.

Authors:  A Tothill
Journal:  Br J Pharmacol Chemother       Date:  1967-03

Review 9.  A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.

Authors:  R T Brittain; G P Levy
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

10.  Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors.

Authors:  J B Farmer; I Kennedy; G P Levy; R J Marshall
Journal:  Br J Pharmacol       Date:  1972-08       Impact factor: 8.739
  10 in total
  5 in total

Review 1.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

2.  Some further evidence for partial agonist activity of labetalol.

Authors:  A J Riley
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

3.  Failure of enhancement by labetalol of bronchopulmonary effects of histamine in guinea-pigs: independence of alpha-adrenoceptor antagonism.

Authors:  C Clerici; A Harf; I Macquin-Mavier
Journal:  Br J Pharmacol       Date:  1987-07       Impact factor: 8.739

4.  Circulatory and metabolic effects of a combined alpha- and beta-adrenoceptor blocker (labetalol) in hypertension of pregnancy.

Authors:  N O Lunell; P Hjemdahl; B B Fredholm; H Nisell; B Persson; J Wager
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

Review 5.  Pharmacology of combined alpha-beta-blockade. I.

Authors:  W J Louis; J J McNeil; O H Drummer
Journal:  Drugs       Date:  1984       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.